Redeye reiterates its positive long-term view on Genovis and raises estimates somewhat on the back of Q1’20 results which, on balance, we believe bode well for the future. While the corona crisis may compromise business near term and certainly in Q2’20, Genovis’s model should prove relatively resilient, in our view. Genovis remains on Redeye’s Conviction Buy List.